Item 8.01 Other Events.

On January 23, 2023, CymaBay Therapeutics, Inc. suspended the use of its prospectus filed with the Securities and Exchange Commission (the "SEC") and dated July 13, 2020 relating to the Controlled Equity OfferingSM Sales Agreement, dated July 2, 2020 (the "Sales Agreement"), by and between CymaBay and Cantor Fitzgerald & Co. CymaBay will not make any sales of common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the SEC. Other than the termination of the prospectus relating to the Sales Agreement, the Sales Agreement remains in full force and effect.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses